 |
 |
|
||||||
|
|
|||||||
|
|
|||||||
 |
|
 |
||||||
| ||||||||
 |
|
 | ||||||
|
| |||||||
|
July 20, 2011, Cleveland, OH - Arteriocyte receives $1 Million award from Ohio Third Frontier Program to advance its NANEX™ technology toward clinical use. Arteriocyte® announced today that the Ohio Department of Development's Third Frontier Commission awarded a $1 million grant to the company for its "Development and Commercialization of Hematopoietic Stem Cell Expansion for Clinical Applications" as part of the Ohio Third Frontier Biomedical Program to accelerate the company's Good Manufacturing Practices (GMP) manufacturing of its NANEX™ technology for clinical use under the product name HemaEx. more... June 7, 2011 - Arteriocyte and the US Army Institute of Surgical Research (USAISR) sign a CRADA to speed development of Cellular Therapies for Orthopaedic Trauma Arteriocyte® announced today that they have entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR) at Fort Sam Houston, Texas. The 3-year CRADA, entitled "The Use of Concentrated Bone Marrow Aspirate from a Point-of-Care Device in Orthopaedic Trauma," enables collaborative investigation of new stem cell based therapies for orthopaedic trauma and related battlefield injuries using Arteriocyte's Magellan® MAR01™ system for rapid bed-side production of cellular therapies and Arteriocyte's NANEX™ rapid stem cell expansion technology. more... | ||||||||
|
|
©Copyright 2007-2014 Arteriocyte. All rights reserved. |
| ||||||
